Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Market sizes and predictions for growth

MarketResearchReports.Biz adds “Global Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug and the growth estimates for the forecasted period.

This report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players active in this space, and also features data for dormant and discontinued projects.

Request Sample Copy of the Report @ https://www.marketresearchreports.biz/sample/sample/1701729

NAFLD and NASH represent considerable burdens for healthcare systems, particularly in developed countries where NAFLD is the most common liver disorder.

NAFLD is strongly related to insulin resistance and is therefore often treated by therapeutics originally intended for use in diabetes mellitus. Up to 80% of obese people have NAFLD, which is usually asymptomatic or mildly symptomatic.

NASH is a severe form of NAFLD. It presents as a swelled or inflamed liver and may result in cirrhosis and consequent liver failure. As populations age the incidence of NASH is likely to rise and become a major healthcare concern for western systems.

Complete Report Details @ https://www.marketresearchreports.biz/reports/1701729/non-alcoholic-fatty-liver-disease-nafld-and-non-alcoholic-steatohepatitis-nash-drug-development-pipeline-review-2018-market-research-reports

Scope

- Which companies are the most active within the pipeline for NAFLD and NASH therapeutics?

- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Request For TOC Report @ https://www.marketresearchreports.biz/reports/1701729/non-alcoholic-fatty-liver-disease-nafld-and-non-alcoholic-steatohepatitis-nash-drug-development-pipeline-review-2018-market-research-reports/toc

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 8

2 Introduction 9

2.1 Gastrointestinal Report Coverage 9

2.2 Non-Alcoholic Steatohepatitis (NASH) - Overview 9

2.3 Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 9

3 Therapeutics Development 10

3.1 Non-Alcoholic Steatohepatitis (NASH) 10

3.2 Non Alcoholic Fatty Liver Disease (NAFLD) 29

4 Therapeutics Assessment 37

4.1 Non-Alcoholic Steatohepatitis (NASH) 37

4.2 Non Alcoholic Fatty Liver Disease (NAFLD) 48

5 Companies Involved in Therapeutics Development 58

5.1 Non-Alcoholic Steatohepatitis (NASH) 58

5.2 Non Alcoholic Fatty Liver Disease (NAFLD) 103

6 Dormant Projects 124

6.1 Non-Alcoholic Steatohepatitis (NASH) 124

6.2 Non Alcoholic Fatty Liver Disease (NAFLD) 127

7 Discontinued Products 129

7.1 Non-Alcoholic Steatohepatitis (NASH) 129

7.2 Non Alcoholic Fatty Liver Disease (NAFLD) 130

8 Product Development Milestones 131

8.1 Non-Alcoholic Steatohepatitis (NASH) 131

8.2 Non Alcoholic Fatty Liver Disease (NAFLD) 143

9 Appendix 158

9.1 Methodology 158

9.2 Coverage 158

9.3 Secondary Research 158

9.4 Primary Research 158

9.5 Expert Panel Validation 158

9.6 Contact Us 159

9.7 Disclaimer 159

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact Us

State Tower

90 State Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-621-2074

Website: https://www.marketresearchreports.biz/

Email: sales@marketresearchreports.biz

This release was published on openPR.